156 related articles for article (PubMed ID: 12384437)
21. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
22. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
[TBL] [Abstract][Full Text] [Related]
23. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Grimwade D; Walker H; Oliver F; Wheatley K; Harrison C; Harrison G; Rees J; Hann I; Stevens R; Burnett A; Goldstone A
Blood; 1998 Oct; 92(7):2322-33. PubMed ID: 9746770
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML.
Nishii K; Usui E; Katayama N; Lorenzo F; Nakase K; Kobayashi T; Miwa H; Mizutani M; Tanaka I; Nasu K; Dohy H; Kyo T; Taniwaki M; Ueda T; Kita K; Shiku H
Leukemia; 2003 Apr; 17(4):731-7. PubMed ID: 12682630
[TBL] [Abstract][Full Text] [Related]
26. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis.
Styczynski J; Wysocki M
Pediatr Blood Cancer; 2004 Feb; 42(2):195-9. PubMed ID: 14752887
[TBL] [Abstract][Full Text] [Related]
28. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
30. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
31. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
32. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Rubnitz JE; Crews KR; Pounds S; Yang S; Campana D; Gandhi VV; Raimondi SC; Downing JR; Razzouk BI; Pui CH; Ribeiro RC
Leukemia; 2009 Aug; 23(8):1410-6. PubMed ID: 19242495
[TBL] [Abstract][Full Text] [Related]
33. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.
Eisele L; Klein-Hitpass L; Chatzimanolis N; Opalka B; Boes T; Seeber S; Moritz T; Flasshove M
Acta Haematol; 2007; 117(1):8-15. PubMed ID: 17095854
[TBL] [Abstract][Full Text] [Related]
35. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
36. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
Taub JW; Matherly LH; Stout ML; Buck SA; Gurney JG; Ravindranath Y
Blood; 1996 Apr; 87(8):3395-403. PubMed ID: 8605357
[TBL] [Abstract][Full Text] [Related]
37. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
Leuk Lymphoma; 2008 Mar; 49(3):508-16. PubMed ID: 18297528
[TBL] [Abstract][Full Text] [Related]
38. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
Stein AS; O'Donnell MR; Slovak ML; Nademanee A; Dagis A; Schmidt GM; Parker PM; Snyder DS; Smith EP; Somlo G; Margolin KA; Arber D; Niland J; Forman SJ
Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
[TBL] [Abstract][Full Text] [Related]
39. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro.
Tosi P; Visani G; Ottaviani E; Testoni N; Pellacani A; Tura S
Eur J Haematol; 1998 Mar; 60(3):161-5. PubMed ID: 9548414
[TBL] [Abstract][Full Text] [Related]
40. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience.
Razzouk BI; Raimondi SC; Srivastava DK; Pritchard M; Behm FG; Tong X; Sandlund JT; Rubnitz JE; Pui CH; Ribeiro RC
Leukemia; 2001 Sep; 15(9):1326-30. PubMed ID: 11516092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
